• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pediatrics

Childhood ADHD, stimulant treatment not linked with height

byJames GrayandLeah Carr, MD
September 1, 2014
in Pediatrics, Psychiatry
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Childhood attention-deficit/hyperactivity disorder (ADHD) diagnosis was not associated with changes in peak height velocity (PHV) or final adult height when compared to undiagnosed individuals.

2. Stimulant treatment for childhood ADHD was associated with a delayed PHV without a significant difference in final adult height when compared to those who went untreated.

Evidence Rating Level: 2 (Good)

Study Rundown: Stimulant treatment for childhood attention-deficit/hyperactivity disorder (ADHD) has long been postulated to affect growth. This study examined the effects of ADHD diagnosis and length of stimulant treatment on various indicators of growth velocity and adult height. The authors found that ADHD itself was not associated with a change in magnitude of peak height velocity (PHV), the age of PHV, or final adult height. While stimulant treatment was not shown to be associated with magnitude of PHV nor final adult height, stimulant-treated males were found to have a delayed PHV without a difference in final adult height. It is unclear how generalizable these results are, as the cohort used in the study was small and homogenous and the accuracy of the height measurements obtained during stimulant treatment is unknown. However, the use of researcher-obtained adult heights adds strength to the conclusion that stimulants may not affect final adult height and therefore should not be a major consideration in the medical management of ADHD.

Click to read the study, published today in Pediatrics

Relevant Reading: National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: 24-Month Outcomes of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder

Study Author, William J. Barbaresi, MD, talks to 2 Minute Medicine: Director, Developmental Medicine Center, Boston Children’s Hospital; Associate Chief, Division of Developmental Medicine; Wade Family Foundation Chair in Developmental Medicine; Associate Professor of Pediatrics, Harvard Medical School.

RELATED REPORTS

Use of mobile devices for calming associated with increased emotional reactivity in some children

Early childhood smoke exposure associated with negative neurocognitive outcomes in children

FOCAL+ training program reduces the rate of collisions in teenage drivers with ADHD

“Although stimulant medications have been in use for decades, and studies have attempted to address the concern that stimulant treatment may adversely impact growth, this issue has remained unanswered and controversial. Almost every parent who is considering stimulant treatment for their child with ADHD asks about the impact on growth. This study provides the first large, population-based, long-term study of stimulant treatment and growth from childhood through adulthood.  The results indicate that stimulant treatment did not have a significant impact on growth patterns or on final adult height, a finding which should provide some reassurance to parents who are considering treatment for their child with ADHD and for the clinicians who are working with these families.”

In-Depth [prospective and retrospective cohort study]: A birth cohort from 1976-1982 from the Rochester Epidemiology Cohort provided ADHD cases and non-ADHD gender- and age-matched controls for study inclusion. A total of 243 ADHD cases (72.6% male, N = 171 simulant-treated, N = 65 untreated) and 394 non-ADHD age-matched controls (72% male) were included. Participant heights and stimulant treatment information were retrospectively obtained from clinical records and adult height was followed from 2010 onward. ADHD cases were considered stimulant-treated if participants received a cumulative duration of treatment for ≥3 months between the ages of 2 and 20 years. No significant difference in adult height magnitude of PHV, or age of PHV occurrence between ADHD cases and controls was observed in either gender; however, the mean age of PHV among males was significantly later in stimulant-treated ADHD cases when compared to untreated ADHD cases (13.5 years ± 1.0 vs. 12.9 years ± .2, P = 0.002). There was no significant difference in adult height between stimulant-treated ADHD cases and untreated ADHD cases as well as no significant correlation between stimulant treatment duration and adult height in either gender.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: ADHDadult heightchildhood growthdevelopment
Previous Post

Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]

Next Post

2 Minute Medicine Rewind August 25 – September 1, 2014

RelatedReports

Adolescent mothers in protective care more likely to have their children placed in care
Neurology

Use of mobile devices for calming associated with increased emotional reactivity in some children

January 2, 2023
Adolescent smoking heavily influenced by parents and siblings
Chronic Disease

Early childhood smoke exposure associated with negative neurocognitive outcomes in children

December 26, 2022
65% of alcohol-related childhood vehicular deaths related to riding with drunk drivers
Neurology

FOCAL+ training program reduces the rate of collisions in teenage drivers with ADHD

December 8, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: A Misconception about Miscarriage, Scandal and ADHD, 10000 Steps per Day and Marijuana During Pregnancy!

October 4, 2022
Next Post
2 Minute Medicine Rewind August 25 – September 1, 2014

2 Minute Medicine Rewind August 25 – September 1, 2014

Added sugar intake associated with mortality from cardiovascular disease

Diabetes in males on the rise, linked to obesity epidemic

Overall US diet quality improved from 1999 to 2010

Overall US diet quality improved from 1999 to 2010

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options